Antibiotics are a key component in the global effort to eliminate trachoma, the world’s leading infectious cause of blindness. One of several neglected tropical diseases (NTDs) the World Health Organization (WHO) has identified for elimination, trachoma is a preventable disease, and one that affects those living in communities with limited access to healthcare, clean water and sanitation.
Neglected tropical diseases (NTDs) affect over one billion people worldwide. This group of viral, bacterial and parasitic diseases can be found in 149 countries – that’s 76 percent of countries in the world – and most often affects impoverished populations, who lack access to clean water or sanitation and live in close contact with infectious vectors. The effects of NTDs on communities can be devastating – keeping children out of school and preventing adults from going to work or caring for themselves or their families.
Pfizer has long been a partner in the global effort to eliminate trachoma, the world’s leading infectious cause of blindness, through its donation of an oral antibiotic that can help treat and prevent the debilitating disease. Now, Pfizer has announced that it will extend its donation of the antibiotic through 2025, building on the company’s 20-year support of a partnership to eliminate this disease.
When Dr. Charles A. Knirsch, MD, MPH, joined Pfizer more than 20 years ago, planning had just begun for a new partnership to eliminate trachoma, a neglected tropical disease and the world’s leading infectious cause of blindness.
The New England Journal of Medicine has published results from a new study showing that the use of an antibiotic significantly reduced mortality among children living in three low-income countries in Sub-Saharan Africa.
Novartis has received approval for its new powdered formulation for an inhaled cystic fibrosis therapy. The inhaled antibiotic was recommended to regulators for approval by an FDA advisory panel. Novartis’s previous delivery system earned sales of $300 million dollars last year.